Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
| All Releases |
|---|
 |
Corgentech to Announce Second Quarter 2005 Financial Results and Host Webcast Conference Call on July 26, 2005
Jul 19, 2005
|
67.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., July 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, will announce financial results for the second quarter 2005 after the markets close on Tuesday, July 26, 2005 and will hold a webcast teleconference at 4:30 p.m. Eastern time that day. John McLaughlin, Corgentech...
|
|
|
Corgentech Presents Preclinical Data Demonstrating Reduction of Inflammation Using New Drug Candidate for Inflammatory Bowel Disease
Jun 27, 2005
|
68.6 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that its NF-kappaB Decoy (NF-kappaB Decoy) drug candidate was effective in preclinical studies in reducing disease activity in acute and chronic models of Crohn's disease and ulcerative colitis-both also referred to as inf...
|
|
|
Corgentech to Present at the Pacific Growth Equities Life Sciences Growth Conference
Jun 1, 2005
|
63.7 KB
|
| |
SOUTH SAN FRANCISCO, Calif., June 1, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Pacific Growth Equities Life Sciences Growth Conference on June 8, 2005 at 8:30 a.m. PDT in San Fra...
|
|
|
Corgentech Treats First Patient in Phase 1/2 Trial of New Drug Candidate for Eczema
May 24, 2005
|
71.0 KB
|
| |
SOUTH SAN FRANCISCO, Calif., May 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK) today announced that the company has begun treating patients in a multi-center Phase 1/2 clinical trial of its NF-kappaB Decoy (NF-kB Decoy) drug candidate for the treatment of atopic dermatitis, a chronic skin disease also known as eczema...
|
|
|
Corgentech to Present at Needham & Company Fourth Annual Biotechnology Conference
May 19, 2005
|
65.9 KB
|
| |
SOUTH SAN FRANCISCO, Calif., May 19, 2005 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Needham & Company Fourth Annual Biotechnology Conference on May 26, 2005 at 11:30 a.m. EDT in New Y...
|
|
|
Click here to download our most recent fact sheet.